These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

709 related articles for article (PubMed ID: 28221868)

  • 1. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition.
    Lheureux S; Bruce JP; Burnier JV; Karakasis K; Shaw PA; Clarke BA; Yang SY; Quevedo R; Li T; Dowar M; Bowering V; Pugh TJ; Oza AM
    J Clin Oncol; 2017 Apr; 35(11):1240-1249. PubMed ID: 28221868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer.
    Parkes EE; Kennedy RD
    Oncologist; 2016 May; 21(5):586-93. PubMed ID: 27022037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval.
    Fong PC; Yap TA; Boss DS; Carden CP; Mergui-Roelvink M; Gourley C; De Greve J; Lubinski J; Shanley S; Messiou C; A'Hern R; Tutt A; Ashworth A; Stone J; Carmichael J; Schellens JH; de Bono JS; Kaye SB
    J Clin Oncol; 2010 May; 28(15):2512-9. PubMed ID: 20406929
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer.
    Rafii S; Gourley C; Kumar R; Geuna E; Ern Ang J; Rye T; Chen LM; Shapira-Frommer R; Friedlander M; Matulonis U; De Greve J; Oza AM; Banerjee S; Molife LR; Gore ME; Kaye SB; Yap TA
    Oncotarget; 2017 Jul; 8(29):47154-47160. PubMed ID: 28454085
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of BRCA1 and BRCA2 mutation testing to target PARP inhibitor use in platinum-sensitive recurrent ovarian cancer.
    Secord AA; Barnett JC; Ledermann JA; Peterson BL; Myers ER; Havrilesky LJ
    Int J Gynecol Cancer; 2013 Jun; 23(5):846-52. PubMed ID: 23666017
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Abnormalities of DNA repair and gynecological cancers].
    Auguste A; Leary A
    Bull Cancer; 2017 Nov; 104(11):971-980. PubMed ID: 29054544
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy.
    Domchek SM; Aghajanian C; Shapira-Frommer R; Schmutzler RK; Audeh MW; Friedlander M; Balmaña J; Mitchell G; Fried G; Stemmer SM; Hubert A; Rosengarten O; Loman N; Robertson JD; Mann H; Kaufman B
    Gynecol Oncol; 2016 Feb; 140(2):199-203. PubMed ID: 26723501
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
    Moore K; Colombo N; Scambia G; Kim BG; Oaknin A; Friedlander M; Lisyanskaya A; Floquet A; Leary A; Sonke GS; Gourley C; Banerjee S; Oza A; González-Martín A; Aghajanian C; Bradley W; Mathews C; Liu J; Lowe ES; Bloomfield R; DiSilvestro P
    N Engl J Med; 2018 Dec; 379(26):2495-2505. PubMed ID: 30345884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cediranib, a pan-VEGFR inhibitor, and olaparib, a PARP inhibitor, in combination therapy for high grade serous ovarian cancer.
    Ivy SP; Liu JF; Lee JM; Matulonis UA; Kohn EC
    Expert Opin Investig Drugs; 2016; 25(5):597-611. PubMed ID: 26899229
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biological and clinical evidence for somatic mutations in BRCA1 and BRCA2 as predictive markers for olaparib response in high-grade serous ovarian cancers in the maintenance setting.
    Dougherty BA; Lai Z; Hodgson DR; Orr MCM; Hawryluk M; Sun J; Yelensky R; Spencer SK; Robertson JD; Ho TW; Fielding A; Ledermann JA; Barrett JC
    Oncotarget; 2017 Jul; 8(27):43653-43661. PubMed ID: 28525389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PARP inhibitor maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer: a cost-effectiveness analysis.
    Smith HJ; Walters Haygood CL; Arend RC; Leath CA; Straughn JM
    Gynecol Oncol; 2015 Oct; 139(1):59-62. PubMed ID: 26303225
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial.
    Ledermann JA; Harter P; Gourley C; Friedlander M; Vergote I; Rustin G; Scott C; Meier W; Shapira-Frommer R; Safra T; Matei D; Fielding A; Spencer S; Rowe P; Lowe E; Hodgson D; Sovak MA; Matulonis U
    Lancet Oncol; 2016 Nov; 17(11):1579-1589. PubMed ID: 27617661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-Term Responders on Olaparib Maintenance in High-Grade Serous Ovarian Cancer: Clinical and Molecular Characterization.
    Lheureux S; Lai Z; Dougherty BA; Runswick S; Hodgson DR; Timms KM; Lanchbury JS; Kaye S; Gourley C; Bowtell D; Kohn EC; Scott C; Matulonis U; Panzarella T; Karakasis K; Burnier JV; Gilks CB; O'Connor MJ; Robertson JD; Ledermann J; Barrett JC; Ho TW; Oza AM
    Clin Cancer Res; 2017 Aug; 23(15):4086-4094. PubMed ID: 28223274
    [No Abstract]   [Full Text] [Related]  

  • 14. Radiosensitization by the PARP inhibitor olaparib in BRCA1-proficient and deficient high-grade serous ovarian carcinomas.
    Bi Y; Verginadis II; Dey S; Lin L; Guo L; Zheng Y; Koumenis C
    Gynecol Oncol; 2018 Sep; 150(3):534-544. PubMed ID: 30025822
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The status of poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors in ovarian cancer, part 2: extending the scope beyond olaparib and BRCA1/2 mutations.
    Miller RE; Ledermann JA
    Clin Adv Hematol Oncol; 2016 Sep; 14(9):704-11. PubMed ID: 27673289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial.
    Audeh MW; Carmichael J; Penson RT; Friedlander M; Powell B; Bell-McGuinn KM; Scott C; Weitzel JN; Oaknin A; Loman N; Lu K; Schmutzler RK; Matulonis U; Wickens M; Tutt A
    Lancet; 2010 Jul; 376(9737):245-51. PubMed ID: 20609468
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.
    Pujade-Lauraine E; Ledermann JA; Selle F; Gebski V; Penson RT; Oza AM; Korach J; Huzarski T; Poveda A; Pignata S; Friedlander M; Colombo N; Harter P; Fujiwara K; Ray-Coquard I; Banerjee S; Liu J; Lowe ES; Bloomfield R; Pautier P;
    Lancet Oncol; 2017 Sep; 18(9):1274-1284. PubMed ID: 28754483
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Olaparib maintenance monotherapy in platinum-sensitive, relapsed ovarian cancer without germline
    Poveda AM; Davidson R; Blakeley C; Milner A
    Future Oncol; 2019 Nov; 15(32):3651-3663. PubMed ID: 31553234
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial.
    Ledermann J; Harter P; Gourley C; Friedlander M; Vergote I; Rustin G; Scott CL; Meier W; Shapira-Frommer R; Safra T; Matei D; Fielding A; Spencer S; Dougherty B; Orr M; Hodgson D; Barrett JC; Matulonis U
    Lancet Oncol; 2014 Jul; 15(8):852-61. PubMed ID: 24882434
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Olaparib as first line in BRCA-mutated advanced ovarian carcinoma: Is it cost-effective in Spain?
    Moya-Alarcón C; González-Domínguez A; Ivanova-Markova Y; Gimeno-Ballester V; Barretina-Ginesta MP; Pérez-Fidalgo JA; Redondo A
    Gynecol Oncol; 2022 Feb; 164(2):406-414. PubMed ID: 34844775
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.